A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of MZE001 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects
Latest Information Update: 24 Mar 2023
At a glance
- Drugs MZE 001 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; First in man
- Sponsors Maze Therapeutics
Most Recent Events
- 22 Mar 2023 Results published in the Media Release
- 22 Mar 2023 According to a Maze media release, data from this study data are being presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Dallas.
- 27 Feb 2023 According to Maze media release, company announced positive results from this study.